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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
policosanols from sugar cane wax and maintenance of normal blood 
LDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 4693) and 
maintenance of normal blood HDL-cholesterol concentrations (ID 1747, 
1748, 1864, 1951, 1954, 4693) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to policosanols from sugar cane wax and maintenance of normal blood LDL-cholesterol 
concentrations and maintenance of normal blood HDL-cholesterol concentrations. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituent that is the subject of the health claims is policosanols from sugar cane wax. The 
Panel considers that policosanols from sugar cane wax are sufficiently characterised. 
Maintenance of normal blood LDL-cholesterol concentrations  
The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and “cardiovascular 
system”. The target population is assumed to be the general population. In the context of the proposed 
wordings, the Panel assumes that the claimed effects refer to the maintenance of normal blood 
                                                     
1 On request from the European Commission, Question No EFSA-Q-2008-2480, EFSA-Q-2008-2481, EFSA-Q-2008-2597, 
EFSA-Q-2008-2684, EFSA-Q-2008-2687, EFSA-Q-2010-00646, adopted on 08 April 2011. 
2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Cardiovascular Health/Oxidative Stress: Antti Aro, Marianne Geleijnse, Marina Heinonen, Ambroise Martin, Wilhelm 
Stahl and Henk van den Berg. 
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LDL-cholesterol concentrations. The Panel considers that maintenance of normal blood 
LDL-cholesterol concentrations is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the results from human intervention studies 
which assessed the effects of policosanols from sugar cane wax on total and LDL-cholesterol 
concentrations were inconsistent, and that no evidence for a mechanism by which policosanols from 
sugar cane wax could exert the claimed effect has been provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of policosanols from sugar cane wax and maintenance of 
normal blood LDL-cholesterol concentrations. 
Maintenance of normal blood HDL-cholesterol concentrations  
The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and “cardiovascular 
system”. The target population is assumed to be the general population. In the context of the proposed 
wordings, the Panel assumes that the claimed effects refer to the maintenance of normal 
HDL-cholesterol concentrations. The Panel considers that maintenance of normal HDL-cholesterol 
concentrations (without increasing LDL-cholesterol concentrations) is a beneficial physiological 
effect. 
In weighing the evidence, the Panel took into account that the results from human intervention studies 
which assessed the effects of policosanols from sugar cane wax on HDL-cholesterol concentrations 
were inconsistent, and that no evidence for a mechanism by which policosanols from sugar cane wax 
could exert the claimed effect has been provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of policosanols from sugar cane wax and maintenance of 
normal blood HDL-cholesterol concentrations.  
KEY WORDS 
Policosanols, sugar cane wax, LDL, HDL, cholesterol, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituents that are the subject of the health claims are “policosanols”, “sugar cane extract” 
and “policosanol/blend of aliphatic alcohols - consisting primarily of 1-Octacosanol, 1-Triacontanol, 
1-Tetracosanol and 1-Hexacosanol - from sugar cane (Saccharum officinarum)”. 
Commercial policosanol preparations are a mixture of long-chain primary alcohols derived from sugar 
cane wax (Saccharum officinarum L.) with chain lengths varying from 24 to 34 carbon atoms. 
Policosanols can also be derived from a variety of other plant sources, including wheat germ oil, and 
their composition depends on the source. 
From the references provided, the Panel assumes that the food constituent which is the subject of the 
health claims is policosanols from sugar cane wax. 
Sugar cane-derived policosanols contain 66-67 % octacosanol (28-C), 12-14 % triacosanol (30-C), 
7-8 % hexacosanol (26-C) and 11-15 % of other carbon alcohols, including tetracosanol (24-C), 
heptacosanol (27-C), nonacosanol (29-C), dotriacontanol (32-C) and tetratriacontanol (34-C) (Natural 
Medicines Comprehensive Database, 2006). 
The Panel considers that the food constituent, policosanols from sugar cane wax, which is the subject 
of the health claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Maintenance of normal blood LDL-cholesterol concentrations (ID 1747, 1748, 1864, 
1951, 1954, 4693) 
The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and “cardiovascular 
system”. The Panel assumes that the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal LDL-cholesterol concentrations. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries.  
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
2.2. Maintenance of normal blood HDL-cholesterol concentrations (ID 1747, 1748, 1864, 
1951, 1954, 4693) 
The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and “cardiovascular 
system”. The Panel assumes that the target population is the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal HDL-cholesterol concentrations.  
High-density lipoproteins (HDL) act as cholesterol scavengers, and are involved in the reverse 
transport of cholesterol in the body (from peripheral tissues back to the liver). Conversely, 
low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries.  
The Panel considers that maintenance of normal HDL-cholesterol concentrations (without increasing 
LDL-cholesterol concentrations) is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
3.1. Maintenance of normal blood LDL-cholesterol concentrations (ID 1747, 1748, 1864, 
1951, 1954, 4693) 
Some of the references provided for the scientific substantiation of the claim reported on health 
outcomes (e.g. platelet aggregation, intermittent claudication, in vitro LDL oxidation) other than 
changes in the blood lipid profile. Also, narrative reviews on the effects of policosanols on blood 
lipids were provided. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
Fourteen references reported on 13 human intervention studies which investigated the effects of 
policosanol consumption on blood lipids. Two references reported on the same study (Kassis and 
Jones, 2006, 2008). 
All of these studies except four (Berthold et al., 2006; Francini-Pesenti et al., 2008a; 2008b; Kassis 
and Jones, 2006, 2008) were conducted in Cuba in Cuban subjects by a single research team using 
policosanols from Cuban sugar cane wax produced by a single company. In these placebo-controlled, 
double-blind, randomised controlled trials, the efficacy of policosanols on blood lipids was studied in 
groups of hypercholesterolaemic subjects (non-insulin dependent diabetics, post-menopausal women, 
elderly, subjects at high risk of coronary heart disease) (Batista et al., 1996; Canetti et al., 1997; 
Castaño et al., 1995; Castaño et al., 1999; 2001; 2005; Crespo et al., 1999; Pons et al., 1994), and in 
one group of healthy subjects (Hernández et al., 1992). Sample sizes varied between 22 and 244 
subjects, doses between 5 and 20 mg policosanols per day, and treatment periods between four weeks 
and 24 months. In one study using 10 mg/day policosanols, subjects (n=85) were followed up for five 
years (open three-year follow up after participation in a two-year controlled intervention trial). 
Efficacy was found to be maintained during this long-term follow up (Canetti et al., 1997). In these 
studies the (statistically significant) reductions reported for total and LDL-cholesterol concentrations 
Policosanols from sugar cane wax related health claims 
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varied between 17-21 % and 21-29 %, respectively. Similar results were reported in a meta-analysis 
of randomised controlled trials in which these studies were included (Chen et al., 2005).  
A multicentre (lipid outpatient clinics and general practitioners in Germany), randomised, 
double-blind, placebo-controlled, parallel group intervention trial was designed to corroborate the 
reported lipid-lowering effects of policosanols from Cuban sugar cane wax. The policosanols used in 
this study were provided by the same company as in the studies described above (Berthold et al., 
2006). A total of 143 subjects with hypercholesterolaemia or combined hyperlipidaemia 
(LDL-cholesterol concentrations >3.88 mmol/L) and either no or one risk factor for cardiovascular 
disease (CVD) other than known coronary heart disease (CHD), or baseline LDL-cholesterol 
concentrations between 3.88 and 4.89 mmol/L and two or more risk factors for CVD, were 
randomised to one of the five following groups after an open-label six-week placebo and diet run-in 
phase: 10 mg/day (n=28), 20 mg/day (n=27), 40 mg/day (n=27), or 80 mg/day (n=32) of policosanols, 
or placebo (n=29). The intervention phase lasted 12 weeks. Sample size was calculated based on the 
percentage change of LDL-cholesterol concentrations from baseline, a level of significance of 
p<0.025 (1-sided), and a power of 80 %. It was expected that the active treatment would result in an 
LDL-cholesterol decrease of at least 10 % (with an SD of 11 %) compared with placebo. To achieve 
the calculated power, 20 patients per intervention group were needed. Results were analysed on an 
intention-to-treat basis. A total of 129 subjects completed the trial. In none of the five treatment 
groups did LDL-cholesterol concentrations decrease more than 10 % from baseline. No statistically 
significant differences between any of the policosanol groups and placebo were observed. There was 
no significant dose-response relationship between policosanol intake and changes in LDL-cholesterol 
concentrations. No statistically significant differences between any of the policosanol groups and 
placebo were observed for any of the secondary outcome measures, i.e. total cholesterol, 
HDL-cholesterol, VLDL-(very low density lipoprotein) cholesterol, triglycerides, lipoprotein(a), and 
ratio of total or LDL- to HDL-cholesterol. The Panel notes that this study does not show an effect of 
policosanols at doses from 10 to 80 mg/day on LDL-cholesterol concentrations.  
In a double-blind, randomised, placebo-controlled study, 68 subjects with LDL-cholesterol 
concentrations between 160 and 250 mg/dL followed a normocaloric diet according to the National 
Cholesterol Education Program Adult Treatment Panel III for three months, and thereafter were 
randomised to consume either two tablets of policosanols (each tablet containing 10 mg policosanols 
from Cuban sugar cane wax) or placebo (calcium phosphate, calcium carbonate and magnesium 
stearate) after dinner for eight weeks, while following their usual lifestyle and a normocaloric diet 
(Francini-Pesenti et al., 2008a). It was estimated that to achieve 80 % power to detect a reduction in 
serum LDL-cholesterol concentrations of 20 % at a 2-sided significance level of 5 %, 30 subjects per 
group would be required. Thirty-one subjects (16 males, mean age 52±6 years) in the policosanol 
group and 32 subjects (14 males, mean age 54±7 years) in the placebo group completed the study. 
Reasons for withdrawal were reported and analyses were provided on completers only. No 
statistically significant changes in total or LDL-cholesterol concentrations (-2.8 mg/dL vs. -2.0 mg/dL, 
p=0.34; -0.9 mg/dL vs. -0.3 mg/dL, p=0.89, respectively) nor in HDL-cholesterol concentrations 
(+1.9 mg/dL vs. +2.9 mg/dL, p=0.66) were observed between the policosanol and the placebo groups. 
The Panel notes that this study does not show an effect of policosanol consumption at doses of 
20 mg/day on blood LDL-cholesterol concentrations. 
The same group conducted another double-blind, randomised, placebo-controlled study in which 
70 subjects with LDL-cholesterol concentrations between 4.0 and 5.2 mmol/L who had reduced their 
LDL-cholesterol concentrations more than 0.3 mmol/L by following a normocaloric diet according to 
the National Cholesterol Education Program Adult Treatment Panel III were randomised to consume 
one tablet daily containing either 10 mg of policosanols from Cuban sugar cane wax or placebo 
(calcium phosphate, calcium carbonate and magnesium stearate) after dinner for eight weeks, while 
following their usual lifestyle and a normocaloric diet (Francini-Pesenti et al., 2008b). Power 
calculations were performed as described in the study by Francini-Pesenti et al. (2008a). Thirty-three 
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subjects (11 males, mean age 48±5 years) in the policosanol group and 31 subjects (14 males, mean 
age 53±6 years) in the placebo group completed the study. Reasons for withdrawal were reported and 
analyses were provided on completers only. No statistically significant changes in total or 
LDL-cholesterol concentrations (-0.01 mmol/L vs. -0.05 mmol/L, p=0.69; -0.01 mmol/L vs. +0.11 
mmol/L, p=0.94 respectively), nor in HDL-cholesterol concentrations (+0.07 mmol/L vs. 
+0.03 mmol/L, p=0.66) were observed between the policosanol and the placebo groups. The Panel 
notes that this study does not show an effect of policosanol consumption at doses of 10 mg/day on 
blood cholesterol concentrations. 
In a double-blind, placebo-controlled, cross-over study by Kassis and Jones (2006, 2008) 22 subjects 
with LDL-cholesterol concentrations between 3.0 and 5.0 mmol/L were recruited to receive either 
10 g margarine containing 10 mg policosanols derived from sugar cane wax or a placebo margarine 
for 28 days each, with a 28-day wash-out period in between. A sample size of 21 was calculated to 
provide an 80 % probability of detecting a difference of 20 % between groups in the parameters 
measured, using a coefficient of variation of 15-20 %. Statistical significance was set at p<0.05. 
Twenty-one subjects (12 males, mean age 57.8±2.1 years) completed the study. On day 25 of each 
study period, subjects were administered 10 g of margarine providing 75 mg of stable isotope-labelled 
cholesterol in order to assess cholesterol absorption. On day 28 of each study period, a dose of 
deuterium oxide was given to subjects in order to determine the amounts of cholesterol biosynthesis 
by measuring deuterium incorporation into red blood cell membrane free cholesterol over 24 hours. 
No statistically significant changes were observed in total or LDL-cholesterol concentrations 
(+1.8±3.0 % vs. -4.0±3.0 %, p=0.18; +4.5±4.0 % vs. -1.6±4.0 %, p=0.28, respectively), nor in HDL-
cholesterol concentrations (-2.7±3.0 % vs. -7.4±3.0 %, p=0.19) between the intervention and placebo 
periods. No statistically significant differences in the area under the curve (AUC) for cholesterol 
absorption or in the fractional rate of cholesterol synthesis were found between the intervention and 
the control periods. The Panel notes that this study does not show an effect of policosanol 
consumption at doses of 10 mg/day on blood cholesterol concentrations, on cholesterol absorption, or 
on the rate of endogenous cholesterol synthesis. 
The Panel notes that although the majority of the studies conducted in Cuban subjects reported 
significant reductions in total and LDL-cholesterol concentrations between 17-21 % and 21-29 % 
respectively following consumption of policosanols from sugar cane wax at doses between 5 and 
20 mg/day, no effect on total or LDL-cholesterol concentrations was found in human intervention 
studies conducted in other parts of the world at doses ranging from 10 to 80 mg/day.  
The Panel also notes that no effect of policosanols from sugar cane wax on cholesterol absorption or 
on the rate of endogenous cholesterol synthesis has been observed in vivo in humans (Kassis and 
Jones, 2006, 2008), and that no evidence for a mechanism by which policosanols could exert the 
claimed effect has been provided.  
In weighing the evidence, the Panel took into account that the results from human intervention studies 
which assessed the effects of policosanols from sugar cane wax on total and LDL-cholesterol 
concentrations are inconsistent, and that no evidence for a mechanism by which policosanols from 
sugar cane wax could exert the claimed effect has been provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of policosanols from sugar cane wax and maintenance of normal blood LDL-cholesterol 
concentrations. 
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3.2.  Maintenance of normal blood HDL-cholesterol concentrations (ID 1747, 1748, 1864, 
1951, 1954, 4693) 
The same human intervention studies described in section 3.1 also reported on the effects of 
consumption of policosanol from sugar cane wax on HDL-cholesterol concentrations. Whereas the 
nine human intervention studies conducted in Cuban subjects generally reported a statistically 
significant increase in HDL-cholesterol concentrations which varied between 8 and 15 % (Batista et 
al., 1996; Canetti et al., 1997; Castaño et al., 1995; Castaño et al., 1999; 2001; 2005; Crespo et al., 
1999; Hernández et al., 1992; Pons et al., 1994), no significant effect was observed in the four studies 
conducted in other parts of the world (Berthold et al., 2006; Francini-Pesenti et al., 2008a; 2008b; 
Kassis and Jones, 2006, 2008), and no evidence for a mechanism by which policosanols from sugar 
cane wax could exert the claimed effect has been provided.  
In weighing the evidence, the Panel took into account that the results from human intervention studies 
which assessed the effects of policosanols from sugar cane wax on HDL-cholesterol concentrations 
are inconsistent, and that no evidence for a mechanism by which policosanols from sugar cane wax 
could exert the claimed effect has been provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of policosanols from sugar cane wax and maintenance of normal blood HDL-cholesterol 
concentrations.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, policosanols from sugar cane wax, which is the subject of the health 
claims, is sufficiently characterised. 
Maintenance of normal blood LDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 
4693) 
 The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and 
“cardiovascular system”. The target population is assumed to be the general population. In the 
context of the proposed wordings, it is assumed that the claimed effects refer to the 
maintenance of normal LDL-cholesterol concentrations. Maintenance of normal blood 
LDL-cholesterol concentrations is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
policosanols from sugar cane wax and maintenance of normal blood LDL-cholesterol 
concentrations. 
Maintenance of normal blood HDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 
4693) 
 The claimed effects are “cholesterol”, “support for healthy blood lipid levels”, and 
“cardiovascular system”. The Panel assumes that the target population is the general 
population. In the context of the proposed wordings, it is assumed that the claimed effects 
refer to the maintenance of normal HDL-cholesterol concentrations. Maintenance of normal 
HDL-cholesterol concentrations (without increasing LDL-cholesterol concentrations) is a 
beneficial physiological effect. 
Policosanols from sugar cane wax related health claims 
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 A cause and effect relationship has not been established between the consumption of 
policosanols from sugar cane wax and maintenance of normal blood HDL-cholesterol 
concentrations.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2480, 
EFSA-Q-2008-2481, EFSA-Q-2008-2597, EFSA-Q-2008-2684, EFSA-Q-2008-2687, EFSA-Q-2010-
00646). The scientific substantiation is based on the information provided by the Member States in 
the consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, 
dose-response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
 
Policosanols from sugar cane wax related health claims 
 
17 EFSA Journal 2011;9(6):2255 
APPENDIX C 
Table 1. Main entry health claims related to policosanols, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1747 Policosanol / Blend of 
aliphatic alcohols - 
consisting primarily of 1-
Octacosanol, 1-
Triacontanol, 1-
Tetracosanol and 1-
Hexacosanol - from sugar 
cane (Saccharum 
officinarum). 
Cholesterol Policosanol helps to maintain healthy 
cholesterol levels / contributes to 
good LDL cholesterol level / 
contributes to good HDL cholesterol 
level 
Conditions of use 
- 5-40 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
1748 Policosanol [from sugarcane 
wax (Saccarum 
officinarum)] 
Support for Healthy 
Blood Lipid Levels 
Support for Healthy Blood Lipid 
Levels/ Natural Blood Lipid Support/ 
Policosanol supports healthy lipid 
metabolism/ Policosanol may 
promote LDL binding, uptake, and 
degradation/ Policosanol may help 
maintain healthy blood pressure 
levels already within normal range 
Conditions of use 
- The recommended daily dosage: 5 to 20 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
1864 Sugar cane extract Cardiovascular system Increases beneficial HDL 
cholesterol./ Beneficial for the heart 
and blood vessels. 
Conditions of use 
- Food supplement containing 10-20 mg of sugar cane extract with policosanol in the daily 
dose. 
 No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1951 
 
Policosanols Cholesterol Helps to decrease cholesterol 
biosynthesis, which is higher during 
the night./ Helps to decrease hepatic 
production of cholesterol, more 
elevated at night./ Helps to control 
blood levels of cholesterol./ Helps to 
improve cholesterol profile. 
Conditions of use 
- At least 5 mg per day 
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ID Food or Food constituent Health Relationship Proposed wording 
1954 Policosanols Cholesterol Helps to decrease cholesterol 
biosynthesis, which is higher during 
the night./ Helps to decrease hepatic 
production of cholesterol, more 
elevated at night. Helps to control 
blood levels of cholesterol./ Helps to 
improve cholesterol profile. 
Conditions of use 
- At least 5 mg per day 
ID Food or Food constituent Health Relationship Proposed wording 
4693 POLICOSANOL Cardiovascular system 
benefit 
Reducing cholesterol levels 
Conditions of use 
- Oral administration, capsules or tablets 
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GLOSSARY AND ABBREVIATIONS 
AUC  Area under the curve  
CVD  Cardiovascular disease  
CHD  Coronary heart disease  
HDL  High-density lipoproteins 
LDL  Low-density lipoproteins 
VLDL  Very low-density lipoproteins 
 
